A Phase 1/2 interventional study of Gilteritinib and Voriconazole in Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 1/2, and was the 1st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–70
Technische Universität Dresden · Sites in Germany
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14+
French Innovative Leukemia Organisation · Sites in France
Ages 18+
By country, each count listing its studies:
gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 10
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 97 across the 31 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc: none open now, 1 under way, none of them phase 3. Of 19 finished, 11 (58%) have results posted.
Among the 22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2013, is one of 7 in phase 1/2, and was the 2nd registered.
Astellas Pharma Inc’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
1 of the studies testing gilteritinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024552H. Lee Moffitt Cancer Center and Research InstituteVyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 22 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
Subject must meet the following criteria as indicated on the clinical laboratory tests*:
Exclusion Criteria:
Subject has had hematopoietic stem cell transplant () and meets any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib · Drug: Voriconazole
Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
Drug: Gilteritinib
Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
Drug: Gilteritinib
Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
Drug: Gilteritinib
Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
Drug: Gilteritinib
Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
Drug: Gilteritinib
Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
Drug: Gilteritinib · Drug: Cephalexin
Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
Drug: Gilteritinib · Drug: Midazolam
Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
Also known as: ASP2215
Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
Number of Participants With Dose Limiting Toxicities (DLTs)
To determine the maximum tolerated dose, safety was assessed by DLTs, defined as any grade ≥ 3 non-hematologic or extramedullary toxicity that occurred within 30 days starting with the first dose taken on day -2, and included the first treatment cycle in the dose escalation phase and in the first treatment cycle (28 days) in the dose expansion phase, that was considered to be possibly or probably related to study drug. Exceptions to this were the following: (1) Alopecia, anorexia or fatigue, (2) Grade 3 nausea and/or vomiting if not required tube feeding or total parenteral nutrition, or diarrhea if not required or prolonged hospitalization that was managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset, (3) Grade 3 fever with neutropenia, with or without infection, (4) Grade 3 infection.
Time frame: From first dose up to end of cycle 1 (30 days)
Number of Participants With Adverse Events (AEs)
Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug (for participants who underwent hematopoietic stem cell transplantation \[HSCT\]: defined as AEs observed after starting study drug until the last dose before on study HSCT plus 30 days, and AEs that began after resumption of gilteritinib and within 30 days after the last dose of gilteritinib). AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (1-Mild, 2-Moderate, 3-Severe, 4-LifeThreatening, 5-Death).
Time frame: From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Area Under the Concentration-time Curve Over the 24-Hour Dosing Interval (AUC24) After Single and Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Maximum Concentration (Cmax) After Single and Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) After Single and Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Time to Observed Cmax (Tmax) After Single and Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Terminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Accumulation Ratio After Multiple Doses of Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Percentage of Participants With Complete Remission (CR) During the First 2 Cycles
CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.
Time frame: During the first 2 cycles (56 days)
Percentage of Participants With CR During Treatment
CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With CR With Incomplete Platelet Recovery (CRp)
CRp was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRp when they achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L). Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With CR With Incomplete Hematological Recovery (CRi)
CRi was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRi when they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required. Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
CRh was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRh when they could not be classified as being in CR and had bone marrow blasts \< 5% and partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CRh was calculated only for participants who were FLT3 mutation positive.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With Composite CR (CRc)
CRc was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRc when they had achieved either CR, complete remission with incomplete platelet recovery (CRp, defined as had achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L) or complete remission with incomplete hematologic recovery (CRi, defined as had fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery; RBC platelet transfusion independence not required). Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With Partial Remission (PR)
PR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in PR when they had bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and with a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate with the total marrow blasts between 5% and 25%. A value of less or equal than 5% blasts was also considered a PR if Auer rods were present. There should be no evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With Best Response
Best response was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). BR was defined as the best measured response for all visits (in the order of CR, CRp, CRi, and PR) post-treatment. Participants who achieved the best response of CR, CRp, CRi or PR were classified as responders. Participants who did not achieve at least PR were considered as non-responders. Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh)
Participants with CR/CRh were defined as participants who achieved either CR or CRh. Participants with CR had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an ANC \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, and normal marrow differential with \< 5% blasts, had been RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). Also, there had been no presence of Auer rods, no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Participants with CRh could not be classified as being in CR and had bone marrow blasts \< 5%, partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CR/CRh was calculated only for participants who were FLT3 mutation positive.
Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CR (DCR)
DCR was defined as the time from the date of first CR until the date of documented relapse for participants who achieved CR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCR was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CRp (DCRp)
DCRp was defined as the time from the date of first CRp until the date of documented relapse for participants who achieved CRp. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCRp was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CRi (DCRi)
DCRi was defined as the time from the date of first CRi until the date of documented relapse for participants who achieved CRi. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRi was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CRh (DCRh)
DCRh was defined as the time from the date of first CRh until the date of documented relapse for participants who achieved CRh but did not have a best response of CR. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRh was calculated only for participants who were FLT3 mutation positive.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CRc (DCRc)
DCRc was defined as the time from the date of first CRc until the date of documented relapse for participants who achieved CRc. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRc was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of CR/CRh (DCRCRh)
DCRCRh was defined as the time from the date of first DCRCRh until the date of documented relapse for participants who achieved CR or CRh. For participants who achieved both CR and CRh, the first CR date or CRh date, whichever occurred first, was used. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRCRh was calculated only for participants who were FLT3 mutation positive.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Duration of Response
Duration of response was defined as the time from the date of either first CRc or PR until the date of documented relapse of any type for participants who achieved CRc or PR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study are considered non-events and censored at the last relapse-free assessment date. Duration of response was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to CR (TTCR)
TTCR was defined as the time from the first dose of study drug until the date of first CR.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to CRp (TTCRp)
TTCRp was defined as the time from the first dose of study drug until the date of first CRp. TTCRp was evaluated for participants who achieved CRp.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to CRi (TTCRi)
TTCRi was defined as the time from the first dose of study drug until the date of first CRi. TTCRi was evaluated for participants who achieved CRi.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to First CR/CRh (TTFCRCRh)
TTFCRCRh was defined as the time from the first dose of study drug until the date of first either CR or CRh. TTFCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date or CRh date, whichever occurs first was used. TTFCRCRh was calculated only for participants who were FLT3 mutation positive.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to Best CR/CRh (TTBCRCRh)
TTBCRCRh was defined as the time from the first dose of study drug until the first date that the best response of CR or CRh was achieved. TTBCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date was used. TTBCRCRh was calculated only for participants who were FLT3 mutation positive.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to CRc (TTCRc)
TTCRc was defined as the time from the first dose of study drug until the date of first CRc. TTCRc was evaluated for participants who achieved CRc.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to Response (TTR)
TTR was defined as the time from the first dose of study drug until the date of either first CRc or PR. TTR was evaluated for participants who achieved CRc or PR.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Time to Best Response (TTBR)
TTBR was defined as the time from the first dose of study drug until the first disease assessment date when participant achieved best response. TTBR was evaluated in participants who achieved best response of CR, CRp, CRi, or PR.
Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Overall Survival (OS)
The time from the date of first dose of study drug until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. OS was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Event Free Survival (EFS)
EFS was defined as the time from the date of first dose of study drug until the date of documented relapse, treatment failure or death from any cause, whichever occurred first. For a participant with none of these events, EFS was censored at the date of last relapse-free disease assessment. A participant without post-treatment disease assessment was censored at randomization date. Treatment failure included those participants who discontinued the treatment due to "progressive disease" or "lack of efficacy" without a previous response of CR, CRp, CRi or PR. Treatment failure date referred to the start of new anti-leukemia therapy or the last treatment evaluation date when new anti-leukemia therapy date was not available. For participants who were censored, last relapse-free disease assessment date referred to the participant's last disease assessment date. EFS was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Leukemia Free Survival (LFS)
LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc. For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date. LFS was calculated using Kaplan-Meier method and therefore data are estimated.
Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Percentage of Participants Who Achieved Transfusion Conversion
Participants who achieved transfusion conversion were defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period. Participants were considered baseline transfusion dependent if there were RBC or platelet transfusions within the baseline period. Participants were considered post-baseline transfusion independent if they were on treatment \>=84 days, and if there was one consecutive 56 days without any RBC or platelet transfusion within post-baseline period. If participants were on treatment \>28 days but \<84 days, and there was no RBC or platelet transfusion within post-baseline period, or on treatment \<=28 days, post-baseline transfusion status was not evaluable. Exact 95% confidence interval was estimated using the binomial distribution.
Time frame: Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days
Percentage of Participants Who Achieved Transfusion Maintenance
Participants who achieved transfusion maintenance were defined as the number of participants who were transfusion independent at baseline period and still maintained transfusion independent at post-baseline period divided by the total number of participants who were transfusion independent at baseline period.
Time frame: Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days
AUC24 of Gilteritinib in Co-administration With Voriconazole
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Cmax of Gilteritinib in Co-administration With Voriconazole
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
AUClast of Gilteritinib in Co-administration With Voriconazole
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Tmax of Gilteritinib in Co-administration With Voriconazole
Plasma samples were used for pharmacokinetic assessments.
Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
AUC24 of Midazolam Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
AUC24 of Metabolite 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Cmax of Midazolam Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Cmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
AUClast of Midazolam Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
AUClast of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Tmax of Midazolam Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Tmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Area Under the Concentration-time Curve From the Time of Dosing Extrapolated to Time Infinity (AUCinf) of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Cmax of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
AUClast of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Tmax of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
T1/2 of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Apparent Total Systemic Clearance After Single or Multiple Extravascular Dosing (CL/F) of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Apparent Volume of Distribution During the Terminal Elimination Phase After Single Extravascular Dosing (Vz/F) of Cephalexin Administered With and Without Gilteritinib
Plasma samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Amount of Drug Excreted in Urine (Aelast) of Cephalexin Administered With and Without Gilteritinib
Urine samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
Fraction of Drug Excreted Into Urine in Percentage (%Ae) of Cephalexin Administered With and Without Gilteritinib
Urine samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
Renal Clearance (CLr) of Cephalexin in Administered With and Without Gilteritinib
Urine samples were used for pharmacokinetic assessments.
Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
This dose-escalation/dose-expansion study was conducted in sites in the United States, France, Germany and Italy. The study had 7 dose-escalation cohorts with ≥3 participants enrolled at each dose level. Following escalation to the next dose cohort, additional participants were enrolled to the dose-expansion cohorts per protocol-specified criteria.
| Milestone | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 5 | 3 | 3 | 3 | 4 | 3 | 4 | 11 | 15 | 21 | 69 | 102 | 17 |
| Treated | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 12 | 13 | 21 | 66 | 100 | 17 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 3 | 3 | 3 | 4 | 3 | 4 | 11 | 15 | 21 | 69 | 102 | 17 |
| Withdrew: Never received study drug | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 5 | 21 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 5 | 19 | 2 |
| Withdrew: Lack of efficacy | 1 | 2 | 1 | 1 | 0 | 0 | 1 | 3 | 3 | 3 | 16 | 8 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 6 | 5 | 6 | 22 | 31 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 6 | 10 | 0 |
| Withdrew: Miscellaneous | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 12 | 11 | 1 |
To determine the maximum tolerated dose, safety was assessed by DLTs, defined as any grade ≥ 3 non-hematologic or extramedullary toxicity that occurred within 30 days starting with the first dose taken on day -2, and included the first treatment cycle in the dose escalation phase and in the first treatment cycle (28 days) in the dose expansion phase, that was considered to be possibly or probably related to study drug. Exceptions to this were the following: (1) Alopecia, anorexia or fatigue, (2) Grade 3 nausea and/or vomiting if not required tube feeding or total parenteral nutrition, or diarrhea if not required or prolonged hospitalization that was managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset, (3) Grade 3 fever with neutropenia, with or without infection, (4) Grade 3 infection.
| Participants | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any DLT | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 7 | 15 | 3 |
| Blood and lymphatic system disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cardiac disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Eye disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gastrointestinal disorders | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 1 |
| General disorders & administration site conditions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatobiliary disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections and infestations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Investigations | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 6 | 2 |
| Metabolism and nutrition disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Musculoskeletal and connective tissue disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Nervous system disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 |
| Renal and urinary disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Reproductive system and breast disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Vascular disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug (for participants who underwent hematopoietic stem cell transplantation \[HSCT\]: defined as AEs observed after starting study drug until the last dose before on study HSCT plus 30 days, and AEs that began after resumption of gilteritinib and within 30 days after the last dose of gilteritinib). AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (1-Mild, 2-Moderate, 3-Severe, 4-LifeThreatening, 5-Death).
| Participants | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 12 | 13 | 20 | 64 | 100 | 17 |
| Drug-Related AEs | 3 | 2 | 1 | 3 | 3 | 2 | 3 | 7 | 6 | 17 | 52 | 77 | 13 |
| Deaths | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 3 | 4 | 11 | 23 | 49 | 7 |
| Serious AEs | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 8 | 12 | 19 | 52 | 92 | 14 |
| Drug-Related Serious AEs | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 1 | 10 | 19 | 36 | 4 |
| AEs Leading to Discontinuation of Study Drug | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 5 | 11 | 12 | 46 | 6 |
| Drug-Related AEs Leading to Discont. of Study Drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 5 | 10 | 3 |
| Grade 3 or Higher TEAEs | 3 | 2 | 2 | 1 | 2 | 2 | 3 | 9 | 13 | 20 | 59 | 99 | 14 |
| AEs During On-Study HSCT Period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 0 |
| Serious AEs During On-Study HSCT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Day -2 | 302.1 ± 207.0 | 360.0 ± 223.5 | 1216 ± 472.6 | 2480 ± 1972 | 3022 ± 843.6 | 4163 ± 3178 | 3324 ± 221.1 |
| Cycle 1 Day 15 | 1299 ± 1006 | 2482 ± 33.28 | 6958 ± 3273 | 6943 ± 3221 | 31428 ± 21412 | 31005 ± 10068 | 34768 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| ng/mL | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Day -2 | 28.13 ± 21.49 | 24.98 ± 14.58 | 75.29 ± 25.22 | 136.7 ± 94.37 | 168.2 ± 45.34 | 204.3 ± 136.4 | 207.6 ± 51.81 |
| Cycle 1 day 15 | 64.64 ± 48.77 | 107.6 ± 31.92 | 376.4 ± 150.5 | 374.2 ± 190.1 | 1462 ± 815.1 | 1525 ± 664.6 | 1528 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Day -2 | 303.0 ± 207.1 | 360.4 ± 224.1 | 1216 ± 472.6 | 2480 ± 1972 | 3024 ± 846.2 | 4181 ± 3189 | 2544 ± 1427 |
| Cycle 1 day -15 | 1030 ± 984.2 | 1990 ± 1422 | 7111 ± 3525 | 6943 ± 3221 | 32248 ± 22571 | 31749 ± 10090 | 35506 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Day -2 | 2.00 (0.500 to 4.03) | 5.983 (3.97 to 24.0) | 4.000 (4.00 to 4.08) | 2.083 (2.00 to 3.83) | 5.233 (4.00 to 5.97) | 6.067 (4.08 to 24.1) | 5.783 (4.08 to 5.92) |
| Cycle 1 day 15 | 4.008 (4.00 to 6.00) | 3.867 (0.50 to 6.00) | 4.333 (4.00 to 4.42) | 2.167 (1.95 to 5.75) | 6.033 (6.00 to 6.07) | 6.050 (4.08 to 6.07) | 5.933 (NA to NA) |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib | 62.14 ± 17.88 | 151.8 ± 129.2 | 86.11 ± 24.08 | 45.85 ± 18.83 | 141.9 ± 61.51 | 142.2 ± 55.04 | — |
Plasma samples were used for pharmacokinetic assessments.
| ratio | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio After Multiple Doses of Gilteritinib | 4.259 ± 1.069 | 9.640 ± 7.754 | 5.693 ± 1.442 | 3.290 ± 1.118 | 9.041 ± 3.693 | 9.057 ± 3.303 | — |
CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 0 (NA to NA) | 0 (NA to NA) | 8.3 (0.2 to 38.5) | 3.6 (0.4 to 12.3) | 3.4 (0.7 to 9.5) | 10 (0.3 to 44.5) | 0 (NA to NA) |
| FLT3 Mutation Negative | 50.0 (1.3 to 98.7) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 6.3 (0.2 to 30.2) | 0 (NA to NA) | 4.2 (0.1 to 21.1) | 2.9 (0.3 to 9.9) | 3.0 (0.6 to 8.5) | 5.0 (0.1 to 24.9) | 0 (NA to NA) |
CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 0 (NA to NA) | 0 (NA to NA) | 16.7 (2.1 to 48.4) | 12.5 (5.2 to 24.1) | 11.2 (5.5 to 19.7) | 10.0 (0.3 to 44.5) | 0 (NA to NA) |
| FLT3 Mutation Negative | 50.0 (1.3 to 98.7) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 6.3 (0.2 to 30.2) | 0 (NA to NA) | 8.3 (1.0 to 27.0) | 10.0 (4.1 to 19.5) | 10.0 (4.9 to 17.6) | 5.0 (0.1 to 54.9) | 0 (NA to NA) |
CRp was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRp when they achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L). Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 3.6 (0.4 to 12.3) | 9.0 (4.0 to 16.9) | 10.0 (0.3 to 44.5) | 0 (NA to NA) |
| FLT3 Mutation Negative | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 2.9 (0.3 to 9.9) | 8.0 (3.5 to 15.2) | 5.0 (0.1 to 24.9) | 0 (NA to NA) |
CRi was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRi when they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required. Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 7.1 (0.2 to 33.9) | 0 (NA to NA) | 25.0 (5.5 to 57.2) | 30.4 (18.8 to 44.1) | 20.2 (12.4 to 30.1) | 10.0 (0.3 to 44.5) | 0 (NA to NA) |
| FLT3 Mutation Negative | 0 (NA to NA) | 0 (NA to NA) | 16.7 (2.1 to 48.4) | 7.1 (0.2 to 33.9) | 9.1 (0.2 to 41.3) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 6.3 (0.2 to 30.2) | 0 (NA to NA) | 20.8 (7.1 to 42.2) | 25.7 (16.0 to 37.6) | 19.0 (11.8 to 28.1) | 5.0 (0.1 to 24.9) | 0 (NA to NA) |
CRh was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRh when they could not be classified as being in CR and had bone marrow blasts \< 5% and partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CRh was calculated only for participants who were FLT3 mutation positive.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh) | 7.1 (0.2 to 33.9) | 0 (0 to 0) | 8.3 (0.2 to 38.5) | 10.7 (4.0 to 21.9) | 7.9 (3.2 to 15.5) | 20.0 (2.5 to 55.6) | 0 (0 to 0) |
CRc was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRc when they had achieved either CR, complete remission with incomplete platelet recovery (CRp, defined as had achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L) or complete remission with incomplete hematologic recovery (CRi, defined as had fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery; RBC platelet transfusion independence not required). Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 7.1 (0.2 to 33.9) | 0 (NA to NA) | 41.7 (15.2 to 72.3) | 46.4 (33.0 to 60.3) | 40.4 (30.2 to 51.4) | 30.0 (6.7 to 65.2) | 0 (NA to NA) |
| FLT3 Mutation Negative | 50.0 (1.3 to 98.7) | 0 (NA to NA) | 16.7 (2.1 to 48.4) | 7.1 (0.2 to 33.9) | 9.1 (0.2 to 41.3) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 12.5 (1.6 to 38.3) | 0 (NA to NA) | 29.2 (12.6 to 51.1) | 38.6 (27.2 to 51.0) | 37.0 (27.6 to 47.2) | 15.0 (3.2 to 37.9) | 0 (NA to NA) |
PR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in PR when they had bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and with a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate with the total marrow blasts between 5% and 25%. A value of less or equal than 5% blasts was also considered a PR if Auer rods were present. There should be no evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 7.1 (0.2 to 33.9) | 37.5 (8.5 to 75.5) | 25.0 (5.5 to 57.2) | 7.1 (2.0 to 17.3) | 7.9 (3.2 to 15.5) | 30.0 (6.7 to 65.2) | 50.0 (1.3 to 98.7) |
| FLT3 Mutation Negative | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 7.1 (0.2 to 33.9) | 9.1 (0.2 to 41.3) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 6.3 (0.2 to 30.2) | 18.8 (4.0 to 45.6) | 12.5 (2.7 to 32.4) | 7.1 (2.4 to 15.9) | 8.0 (3.5 to 15.2) | 15.0 (3.2 to 37.9) | 33.3 (0.8 to 90.6) |
Best response was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). BR was defined as the best measured response for all visits (in the order of CR, CRp, CRi, and PR) post-treatment. Participants who achieved the best response of CR, CRp, CRi or PR were classified as responders. Participants who did not achieve at least PR were considered as non-responders. Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 14.3 (1.8 to 42.8) | 37.5 (8.5 to 75.5) | 66.7 (34.9 to 90.1) | 53.6 (39.7 to 67.0) | 48.3 (37.6 to 59.2) | 60.0 (26.2 to 87.8) | 50.0 (1.3 to 98.7) |
| FLT3 Mutation Negative | 50.0 (1.3 to 98.7) | 0 (NA to NA) | 16.7 (2.1 to 48.4) | 14.3 (1.8 to 42.8) | 18.2 (2.3 to 51.8) | 0 (NA to NA) | 0 (NA to NA) |
| All Participants | 18.8 (4.0 to 45.6) | 18.8 (4.0 to 45.6) | 41.7 (22.1 to 63.4) | 45.7 (33.7 to 58.1) | 45.0 (35.0 to 55.3) | 30.0 (11.9 to 54.3) | 33.3 (0.8 to 90.6) |
Participants with CR/CRh were defined as participants who achieved either CR or CRh. Participants with CR had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an ANC \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, and normal marrow differential with \< 5% blasts, had been RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). Also, there had been no presence of Auer rods, no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Participants with CRh could not be classified as being in CR and had bone marrow blasts \< 5%, partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CR/CRh was calculated only for participants who were FLT3 mutation positive.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) | 7.1 (0.2 to 33.9) | 0 (NA to NA) | 25.0 (5.5 to 57.2) | 23.2 (13.0 to 36.4) | 19.1 (11.5 to 28.8) | 30.0 (6.7 to 65.2) | 0 (NA to NA) |
DCR was defined as the time from the date of first CR until the date of documented relapse for participants who achieved CR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCR was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | — | — | NA (NA to NA) | NA (86.0 to NA) | 419.0 (64.0 to NA) | NA (NA to NA) | — |
| FLT3 Mutation Negative | NA (NA to NA) | — | — | — | — | — | — |
| All Participants | NA (NA to NA) | — | NA (NA to NA) | NA (86.0 to NA) | 419.0 (64.0 to NA) | NA (NA to NA) | — |
DCRp was defined as the time from the date of first CRp until the date of documented relapse for participants who achieved CRp. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCRp was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | — | — | NA (NA to NA) | NA (57.0 to NA) | 450.0 (43.0 to NA) | NA (NA to NA) | — |
| All Participants | — | — | NA (NA to NA) | NA (57.0 to NA) | 450.0 (43.0 to NA) | NA (NA to NA) | — |
DCRi was defined as the time from the date of first CRi until the date of documented relapse for participants who achieved CRi. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRi was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | NA (NA to NA) | — | NA (79.0 to NA) | 120.0 (56.0 to 383.0) | 191.0 (57.0 to 420.0) | NA (NA to NA) | — |
| FLT3 Mutation Negative | — | — | 41.0 (22.0 to 60.0) | 99.0 (NA to NA) | — | — | — |
| All Participants | NA (NA to NA) | — | 79.0 (22.0 to NA) | 120.0 (58.0 to 383.0) | 191.0 (57.0 to 420.0) | NA (NA to NA) | — |
DCRh was defined as the time from the date of first CRh until the date of documented relapse for participants who achieved CRh but did not have a best response of CR. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRh was calculated only for participants who were FLT3 mutation positive.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Duration of CRh (DCRh) | NA (NA to NA) | — | NA (NA to NA) | 64.0 (18.0 to 85.0) | 101.0 (29.0 to NA) | NA (NA to NA) | — |
DCRc was defined as the time from the date of first CRc until the date of documented relapse for participants who achieved CRc. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRc was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | NA (NA to NA) | — | NA (79.0 to NA) | 98.0 (57.0 to 307.0) | 191.0 (101.0 to 465.0) | NA (NA to NA) | — |
| FLT3 Mutation Negative | NA (NA to NA) | — | 41.0 (22.0 to 60.0) | 99.0 (NA to NA) | NA (NA to NA) | — | — |
| All Participants | NA (NA to NA) | — | 79.0 (22.0 to NA) | 99.0 (58.0 to 307.0) | 191.0 (101.0 to 465.0) | NA (NA to NA) | — |
DCRCRh was defined as the time from the date of first DCRCRh until the date of documented relapse for participants who achieved CR or CRh. For participants who achieved both CR and CRh, the first CR date or CRh date, whichever occurred first, was used. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRCRh was calculated only for participants who were FLT3 mutation positive.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Duration of CR/CRh (DCRCRh) | NA (NA to NA) | — | NA (NA to NA) | 307.0 (56.0 to NA) | 308.0 (101.0 to NA) | NA (NA to NA) | — |
Duration of response was defined as the time from the date of either first CRc or PR until the date of documented relapse of any type for participants who achieved CRc or PR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study are considered non-events and censored at the last relapse-free assessment date. Duration of response was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | NA (NA to NA) | NA (NA to NA) | 88.0 (9.0 to NA) | 141.0 (58.0 to 383.0) | 220.0 (111.0 to 482.0) | 59.0 (15.0 to 59.0) | NA (NA to NA) |
| FLT3 Mutation Negative | NA (NA to NA) | — | 41.0 (22.0 to 60.0) | 109.5 (99.0 to 120.0) | 85.0 (NA to NA) | — | — |
| All Participants | NA (NA to NA) | NA (NA to NA) | 79.0 (9.0 to NA) | 126.0 (58.0 to 307.0) | 220.0 (85.0 to 482.0) | 59.0 (15.0 to 59.0) | NA (NA to NA) |
TTCR was defined as the time from the first dose of study drug until the date of first CR.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | — | — | 171.5 (28 to 315) | 141.0 (29 to 364) | 93.0 (27 to 225) | 56.0 (56 to 56) | — |
| FLT3 Mutation Negative | 30.0 (30 to 30) | — | — | — | — | — | — |
| All Participants | 30.0 (30 to 30) | — | 171.5 (28 to 315) | 141.0 (29 to 364) | 93.0 (27 to 225) | 56.0 (56 to 56) | — |
TTCRp was defined as the time from the first dose of study drug until the date of first CRp. TTCRp was evaluated for participants who achieved CRp.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | — | — | 140.0 (140 to 140) | 195.0 (30 to 418) | 84.5 (28 to 392) | 29.0 (28 to 30) | — |
| All Participants | — | — | 140.0 (140 to 140) | 195.0 (30 to 418) | 84.5 (28 to 392) | 29.0 (28 to 30) | — |
TTCRi was defined as the time from the first dose of study drug until the date of first CRi. TTCRi was evaluated for participants who achieved CRi.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 57.0 (57 to 57) | — | 57.0 (31 to 70) | 57.0 (26 to 170) | 39.5 (26 to 133) | 28.0 (28 to 28) | — |
| FLT3 Mutation Negative | — | — | 71.5 (71 to 72) | 30.0 (30 to 30) | 30.0 (30 to 30) | — | — |
| All Participants | 57.0 (57 to 57) | — | 64.0 (31 to 72) | 43.5 (26 to 170) | 35.0 (26 to 133) | 28.0 (28 to 28) | — |
TTFCRCRh was defined as the time from the first dose of study drug until the date of first either CR or CRh. TTFCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date or CRh date, whichever occurs first was used. TTFCRCRh was calculated only for participants who were FLT3 mutation positive.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Time to First CR/CRh (TTFCRCRh) | 57.0 (57 to 57) | — | 57.0 (28 to 140) | 59.0 (29 to 280) | 57.0 (27 to 245) | 28.0 (28 to 30) | — |
TTBCRCRh was defined as the time from the first dose of study drug until the first date that the best response of CR or CRh was achieved. TTBCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date was used. TTBCRCRh was calculated only for participants who were FLT3 mutation positive.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| Time to Best CR/CRh (TTBCRCRh) | 57.0 (57 to 57) | — | 57.0 (28 to 315) | 63.0 (29 to 364) | 88.0 (27 to 245) | 30.0 (28 to 56) | — |
TTCRc was defined as the time from the first dose of study drug until the date of first CRc. TTCRc was evaluated for participants who achieved CRc.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 57.0 (57 to 57) | — | 56.0 (28 to 64) | 30.0 (26 to 211) | 31.5 (26 to 197) | 28.0 (28 to 30) | — |
| FLT3 Mutation Negative | 30.0 (30 to 30) | — | 71.5 (71 to 72) | 30.0 (30 to 30) | 30.0 (30 to 30) | — | — |
| All Participants | 43.5 (30 to 57) | — | 57.0 (28 to 72) | 30.0 (26 to 211) | 31.0 (26 to 197) | 28.0 (28 to 30) | — |
TTR was defined as the time from the first dose of study drug until the date of either first CRc or PR. TTR was evaluated for participants who achieved CRc or PR.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 61.5 (29 to 94) | 57.0 (31 to 64) | 31.0 (28 to 59) | 29.0 (26 to 211) | 29.0 (26 to 197) | 28.0 (26 to 61) | 31.0 (31 to 31) |
| FLT3 Mutation Negative | 30.0 (30 to 30) | — | 71.5 (71 to 72) | 29.5 (29 to 30) | 29.5 (29 to 30) | — | — |
| All Participants | 30.0 (29 to 94) | 57.0 (31 to 64) | 43.5 (28 to 72) | 29.0 (26 to 211) | 29.0 (26 to 197) | 28.0 (26 to 61) | 31.0 (31 to 31) |
TTBR was defined as the time from the first dose of study drug until the first disease assessment date when participant achieved best response. TTBR was evaluated in participants who achieved best response of CR, CRp, CRi, or PR.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 75.5 (57 to 94) | 57.0 (31 to 64) | 44.0 (28 to 315) | 43.5 (26 to 364) | 57.0 (26 to 245) | 29.0 (26 to 61) | 31.0 (31 to 31) |
| FLT3 Mutation Negative | 30.0 (30 to 30) | — | 71.5 (71 to 72) | 29.5 (29 to 30) | 29.5 (29 to 30) | — | — |
| All Participants | 57.0 (30 to 94) | 57.0 (31 to 64) | 58.0 (28 to 315) | 30.0 (26 to 364) | 56.0 (26 to 245) | 29.0 (26 to 61) | 31.0 (31 to 31) |
The time from the date of first dose of study drug until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. OS was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 123.0 (17.0 to 267.0) | 199.5 (56.0 to 905.0) | 197.5 (61.0 to 329.0) | 246.0 (190.0 to 309.0) | 214.0 (126.0 to 264.0) | 157.0 (20.0 to 218.0) | 204.0 (51.0 to 357.0) |
| FLT3 Mutation Negative | NA (227.0 to NA) | 71.5 (5.0 to 180.0) | 136.0 (14.0 to 314.0) | 144.0 (83.0 to 195.0) | 67.0 (21.0 to 336.0) | 68.0 (8.0 to 249.0) | 89.0 (NA to NA) |
| All Participants | 149.5 (31.0 to 267.0) | 95.0 (55.0 to 195.0) | 154.0 (74.0 to 299.0) | 216.0 (161.0 to 285.0) | 176.0 (124.0 to 253.0) | 128.5 (36.0 to 199.0) | 89.0 (51.0 to 357.0) |
EFS was defined as the time from the date of first dose of study drug until the date of documented relapse, treatment failure or death from any cause, whichever occurred first. For a participant with none of these events, EFS was censored at the date of last relapse-free disease assessment. A participant without post-treatment disease assessment was censored at randomization date. Treatment failure included those participants who discontinued the treatment due to "progressive disease" or "lack of efficacy" without a previous response of CR, CRp, CRi or PR. Treatment failure date referred to the start of new anti-leukemia therapy or the last treatment evaluation date when new anti-leukemia therapy date was not available. For participants who were censored, last relapse-free disease assessment date referred to the participant's last disease assessment date. EFS was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 52.0 (14.0 to 88.0) | 109.0 (29.0 to 357.0) | 93.5 (61.0 to 127.0) | 112.0 (92.0 to 143.0) | 121.0 (92.0 to 155.0) | 85.0 (11.0 to 157.0) | 86.0 (51.0 to 121.0) |
| FLT3 Mutation Negative | 58.0 (NA to NA) | 39.0 (5.0 to 67.0) | 74.0 (12.0 to 131.0) | 85.5 (37.0 to 126.0) | 45.0 (21.0 to 113.0) | 43.0 (8.0 to 83.0) | 71.0 (NA to NA) |
| All Participants | 58.0 (19.0 to 88.0) | 55.5 (38.0 to 92.0) | 76.0 (61.0 to 119.0) | 108.0 (90.0 to 126.0) | 118.0 (88.0 to 140.0) | 65.0 (20.0 to 100.0) | 71.0 (51.0 to 121.0) |
LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc. For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date. LFS was calculated using Kaplan-Meier method and therefore data are estimated.
| days | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 242.0 (NA to NA) | — | 98.0 (56.0 to 1126.0) | 98.0 (58.0 to 187.0) | 146.0 (47.0 to 247.0) | 296.0 (130.0 to 462.0) | — |
| FLT3 Mutation Negative | NA (NA to NA) | — | 41.0 (22.0 to 60.0) | 99.0 (NA to NA) | 38.0 (NA to NA) | — | — |
| All Participants | 242.0 (NA to NA) | — | 79.0 (22.0 to 1126.0) | 98.0 (58.0 to 187.0) | 146.0 (45.0 to 247.0) | 296.0 (130.0 to 462.0) | — |
Participants who achieved transfusion conversion were defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period. Participants were considered baseline transfusion dependent if there were RBC or platelet transfusions within the baseline period. Participants were considered post-baseline transfusion independent if they were on treatment \>=84 days, and if there was one consecutive 56 days without any RBC or platelet transfusion within post-baseline period. If participants were on treatment \>28 days but \<84 days, and there was no RBC or platelet transfusion within post-baseline period, or on treatment \<=28 days, post-baseline transfusion status was not evaluable. Exact 95% confidence interval was estimated using the binomial distribution.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | 0 (NA to NA) | 0 (NA to NA) | 37.5 (8.5 to 75.5) | 27.5 (14.6 to 43.9) | 40.4 (27.6 to 54.2) | NA (NA to NA) | NA (NA to NA) |
| FLT3 Mutation Negative | NA (NA to NA) | NA (NA to NA) | 12.5 (0.3 to 52.7) | 22.2 (2.8 to 60.0) | 33.3 (4.3 to 77.7) | NA (NA to NA) | NA (NA to NA) |
| All Participants | NA (NA to NA) | NA (NA to NA) | 25.0 (7.3 to 52.4) | 26.5 (14.9 to 41.1) | 39.7 (27.6 to 52.8) | NA (NA to NA) | NA (NA to NA) |
Participants who achieved transfusion maintenance were defined as the number of participants who were transfusion independent at baseline period and still maintained transfusion independent at post-baseline period divided by the total number of participants who were transfusion independent at baseline period.
| percentage of participants | Gilteritinib 20 mg | Gilteritinib 40 mg | Gilteritinib 80 mg | Gilteritinib 120 mg | Gilteritinib 200 mg | Gilteritinib 300 mg | Gilteritinib 450 mg |
|---|---|---|---|---|---|---|---|
| FLT3 Mutation Positive | — | — | 100.0 (2.5 to 100) | 75.0 (19.4 to 99.4) | 80.0 (44.4 to 97.5) | — | 100.0 (2.5 to 100.0) |
| FLT3 Mutation Negative | — | — | — | 33.3 (0.8 to 90.6) | — | — | — |
| All Participants | — | — | 100.0 (2.5 to 100.0) | 57.1 (18.4 to 90.1) | 80.0 (44.4 to 97.5) | — | 100.0 (2.5 to 100.0) |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 20 mg in Expansion Phase |
|---|---|
| AUC24 of Gilteritinib in Co-administration With Voriconazole | 919.3 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| ng/mL | Gilteritinib 20 mg in Expansion Phase |
|---|---|
| Cmax of Gilteritinib in Co-administration With Voriconazole | 63.79 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 20 mg in Expansion Phase |
|---|---|
| AUClast of Gilteritinib in Co-administration With Voriconazole | 919.3 ± NA |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 20 mg in Expansion Phase |
|---|---|
| Tmax of Gilteritinib in Co-administration With Voriconazole | 2.08 (2.08 to 2.08) |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 66.55 ± 57.70 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 81.56 ± 65.84 |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 20.44 ± 24.80 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 23.10 ± 21.64 |
Plasma samples were used for pharmacokinetic assessments.
| ng/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 14.68 ± 8.923 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 18.45 ± 9.452 |
Plasma samples were used for pharmacokinetic assessments.
| ng/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 4.562 ± 2.858 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 5.053 ± 3.158 |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 59.48 ± 59.49 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 82.44 ± 64.25 |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 17.05 ± 24.70 |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 23.58 ± 22.07 |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 0.5000 (0.367 to 2.00) |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 1.00 (0.317 to 4.13) |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 300 mg in Expansion Phase |
|---|---|
| Midazolam Alone (Day -1) | 0.5583 (0.483 to 2.00) |
| Midazolam + Gilteritinib (Cycle 1 Day 15) | 1.00 (0.317 to 4.13) |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 57650 ± 20386 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 51873 ± 18819 |
Plasma samples were used for pharmacokinetic assessments.
| ng/mL | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 17688 ± 6680 |
| Cephalexin + Gilteritinib (Cycle 1 day 15) | 16075 ± 4606 |
Plasma samples were used for pharmacokinetic assessments.
| ng*h/mL | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 53183 ± 26877 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 54963 ± 29531 |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 1.500 (1.00 to 4.02) |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 1.483 (1.00 to 5.88) |
Plasma samples were used for pharmacokinetic assessments.
| hours | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 1.822 ± 0.5914 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 1.827 ± 0.7175 |
Plasma samples were used for pharmacokinetic assessments.
| L/h | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 9.713 ± 3.319 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 10.58 ± 2.977 |
Plasma samples were used for pharmacokinetic assessments.
| liters | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 24.07 ± 7.173 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 25.86 ± 5.346 |
Urine samples were used for pharmacokinetic assessments.
| mg | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 548.9 ± 523.7 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 448.8 ± 306.1 |
Urine samples were used for pharmacokinetic assessments.
| percentage | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 109.8 ± 104.7 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 89.75 ± 61.21 |
Urine samples were used for pharmacokinetic assessments.
| L/h | Gilteritinib 200 mg in Expansion Phase |
|---|---|
| Cephalexin Alone (Day -1) | 8.784 ± 8.727 |
| Cephalexin + Gilteritinib (Cycle 1 Day 15) | 11.04 ± 8.430 |
Collected over From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gilterinib 20 mg in Escalation Phase | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Gilterinib 40 mg in Escalation Phase | 2/3 (66.7%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Gilterinib 80 mg in Escalation Phase | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Gilterinib 120 mg in Escalation Phase | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Gilterinib 200 mg in Escalation Phase | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Gilterinib 300 mg in Escalation Phase | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Gilterinib 450 mg in Escalation Phase | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Gilterinib 20 mg in Expansion Phase | 10/12 (83.3%) | 8/12 (66.7%) | 12/12 (100%) |
| Gilterinib 40 mg in Expansion Phase | 13/13 (100%) | 12/13 (92.3%) | 12/13 (92.3%) |
| Gilterinib 80 mg in Expansion Phase | 21/21 (100%) | 19/21 (90.5%) | 20/21 (95.2%) |
| Gilterinib 120 mg in Expansion Phase | 53/66 (80.3%) | 52/66 (78.8%) | 62/66 (93.9%) |
| Gilterinib 200 mg in Expansion Phase | 82/100 (82%) | 92/100 (92%) | 97/100 (97%) |
| Gilterinib 300 mg in Expansion Phase | 16/17 (94.1%) | 14/17 (82.4%) | 16/17 (94.1%) |
| Event | Gilterinib 20 mg in Escalation Phase | Gilterinib 40 mg in Escalation Phase | Gilterinib 80 mg in Escalation Phase | Gilterinib 120 mg in Escalation Phase | Gilterinib 200 mg in Escalation Phase | Gilterinib 300 mg in Escalation Phase | Gilterinib 450 mg in Escalation Phase | Gilterinib 20 mg in Expansion Phase | Gilterinib 40 mg in Expansion Phase | Gilterinib 80 mg in Expansion Phase | Gilterinib 120 mg in Expansion Phase | Gilterinib 200 mg in Expansion Phase | Gilterinib 300 mg in Expansion Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/5 | 1/3 | 1/3 | 1/3 | 2/3 | 2/3 | 0/3 | 4/12 | 7/13 | 5/21 | 18/66 | 35/100 | 4/17 |
| PneumoniaInfections and infestations | 0/5 | 1/3 | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 1/12 | 1/13 | 2/21 | 13/66 | 12/100 | 1/17 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 2/3 | 0/3 | 1/3 | 0/3 | 1/3 | 0/3 | 2/12 | 3/13 | 5/21 | 9/66 | 20/100 | 4/17 |
| AnaemiaBlood and lymphatic system disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/12 | 0/13 | 1/21 | 0/66 | 4/100 | 0/17 |
| Cardiac arrestCardiac disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/12 | 0/13 | 1/21 | 0/66 | 0/100 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/12 | 0/13 | 1/21 | 5/66 | 5/100 | 0/17 |
| EnteritisGastrointestinal disorders | 0/5 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 0/13 | 0/21 | 0/66 | 0/100 | 0/17 |
| Mucosal inflammationGeneral disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/12 | 0/13 | 0/21 | 0/66 | 1/100 | 1/17 |
| PyrexiaGeneral disorders | 0/5 | 0/3 | 0/3 | 1/3 | 1/3 | 1/3 | 0/3 | 0/12 | 0/13 | 0/21 | 9/66 | 9/100 | 1/17 |
| CholecystitisHepatobiliary disorders | 0/5 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/12 | 0/13 | 0/21 | 0/66 | 0/100 | 0/17 |
| Event | Gilterinib 20 mg in Escalation Phase | Gilterinib 40 mg in Escalation Phase | Gilterinib 80 mg in Escalation Phase | Gilterinib 120 mg in Escalation Phase | Gilterinib 200 mg in Escalation Phase | Gilterinib 300 mg in Escalation Phase | Gilterinib 450 mg in Escalation Phase | Gilterinib 20 mg in Expansion Phase | Gilterinib 40 mg in Expansion Phase | Gilterinib 80 mg in Expansion Phase | Gilterinib 120 mg in Expansion Phase | Gilterinib 200 mg in Expansion Phase | Gilterinib 300 mg in Expansion Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 1/5 | 0/3 | 1/3 | 0/3 | 3/3 | 1/3 | 1/3 | 4/12 | 5/13 | 8/21 | 27/66 | 32/100 | 4/17 |
| ConstipationGastrointestinal disorders | 1/5 | 1/3 | 1/3 | 2/3 | 1/3 | 1/3 | 0/3 | 1/12 | 1/13 | 5/21 | 12/66 | 32/100 | 1/17 |
| NauseaGastrointestinal disorders | 2/5 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/12 | 3/13 | 4/21 | 15/66 | 28/100 | 1/17 |
| VomitingGastrointestinal disorders | 1/5 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 2/12 | 1/13 | 5/21 | 13/66 | 22/100 | 1/17 |
| Aspartate aminotransferase increasedInvestigations | 0/5 | 0/3 | 1/3 | 0/3 | 1/3 | 1/3 | 2/3 | 1/12 | 1/13 | 3/21 | 20/66 | 35/100 | 1/17 |
| Decreased appetiteMetabolism and nutrition disorders | 0/5 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/12 | 1/13 | 3/21 | 11/66 | 19/100 | 1/17 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/5 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 2/3 | 0/12 | 0/13 | 0/21 | 5/66 | 14/100 | 0/17 |
| PollakiuriaRenal and urinary disorders | 0/5 | 0/3 | 0/3 | 0/3 | 0/3 | 2/3 | 0/3 | 0/12 | 1/13 | 0/21 | 0/66 | 7/100 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 0/3 | 1/3 | 1/3 | 0/3 | 1/3 | 1/3 | 1/12 | 2/13 | 5/21 | 27/66 | 45/100 | 5/17 |
| HypokalaemiaMetabolism and nutrition disorders | 1/5 | 0/3 | 1/3 | 0/3 | 0/3 | 1/3 | 0/3 | 5/12 | 2/13 | 2/21 | 10/66 | 25/100 | 0/17 |
The analysis population was the safety analysis set (SAF), which consisted of all participants who received at least 1 dose of study drug and excluded re-enrolled participants.
| Age, Continuous(years) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 65.8 ± 6.8 | 56.7 ± 6.7 | 61 ± 8.7 | 61.7 ± 6 | 64 ± 1 | 55.3 ± 25 | 61.7 ± 10.7 | 59.3 ± 15.6 | 59.6 ± 14 | 56.3 ± 18.1 | 58.3 ± 16.7 | 59.8 ± 14.6 | 57.7 ± 15.9 | 59 ± 15.1 |
| Sex: Female, Male(Participants) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 1 | 2 | 1 | 0 | 8 | 4 | 12 | 37 | 49 | 5 | 123 |
| Male | 3 | 2 | 2 | 2 | 1 | 2 | 3 | 4 | 9 | 9 | 29 | 51 | 12 | 129 |
| Race/Ethnicity, Customized(Participants) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black or African American | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 4 | 2 | 4 | 3 | 16 |
| White | 5 | 2 | 3 | 2 | 1 | 3 | 3 | 10 | 9 | 14 | 57 | 91 | 13 | 213 |
| Asian | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 7 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 6 | 1 | 1 | 16 |
| Ethnicity(Participants) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Hispanic or Latino | 5 | 3 | 2 | 3 | 3 | 3 | 3 | 11 | 12 | 20 | 62 | 97 | 17 | 241 |
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 3 | 0 | 11 |
| Duration of Disease (AML)(months) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 19.70 ± 24.62 | 10.81 ± 8.58 | 62.46 ± 6.97 | 49.53 ± 72.17 | 9.46 ± 2.23 | 19.75 ± NA | 7.21 ± 4.27 | 11.3 ± 6.61 | 10.53 ± 11.22 | 16.3 ± 9.85 | 12.65 ± 11.33 | 10.9 ± 9.94 | 12.09 ± 17.76 | 13.16 ± 14.97 |
| Local FLT3 Mutation Status(Participants) | Gilteritinib 20 mg in Escalation Phase | Gilteritinib 40 mg in Escalation Phase | Gilteritinib 80 mg in Escalation Phase | Gilteritinib 120 mg in Escalation Phase | Gilteritinib 200 mg in Escalation Phase | Gilteritinib 300 mg in Escalation Phase | Gilteritinib 450 mg in Escalation Phase | Gilteritinib 20 mg in Expansion Phase | Gilteritinib 40 mg in Expansion Phase | Gilteritinib 80 mg in Expansion Phase | Gilteritinib 120 mg in Expansion Phase | Gilteritinib 200 mg in Expansion Phase | Gilteritinib 300 mg in Expansion Phase | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 8 | 12 | 13 | 10 | 9 | 58 |
| Positive | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 11 | 5 | 9 | 53 | 90 | 8 | 194 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Oct 2013 to primary completion in Aug 2017, 45 months.
Results were first posted in Feb 2019, 1 year 6 months after primary completion. A results delay was requested in Nov 2016.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 45 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gilteritinib
Astellas Pharma Global Development, Inc. →